Evgen Pharma PLC – Full Year Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its final results for the year ended 31 March 2019.

Highlights 

• Clinical proof of concept clearly demonstrated in final top line data released from STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) Phase IIa clinical study
• Dosing and three month visits completed in ongoing SAS (SFX-01 After Subarachnoid Haemorrhage) Phase IIb clinical study. Results expected in Q3 or early Q4 of this calendar year
• SFX-01 featured in a Nature Reviews Drug Discovery as a prominent Nrf2/KEAP1 activator
• Susan Clement-Davies, ex-Torreya and Citigroup, appointed as Non-Executive Director
• First European notice of grant for SFX-01 composition of matter patent
• Financial performance in line with expectations:
  – Total comprehensive loss of £2.6m (2018: loss of £2.6m)
  – Net cash outflow of £1.6m (2018: outflow of 0.2m)
  – Cash and short-term investments and cash on deposit at 31 March 2019 of £2.0m (31 March 2018: £3.6m)
• Heavily oversubscribed fundraising in May 2019 raised £5.0m before expenses

Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma, said:

“This has been an exciting year for Evgen. With our positive Phase II breast cancer data already announced, and further clinical data due this year, we look forward to maintaining the momentum in our development programmes and continuing to create value in the business.”